Table 2.
CARBO4 (93 dogs) | CARBO6 (91 dogs) | CARBODOX6 (97 dogs) | DOX5.2 (124 dogs) | DOX5.3 (65 dogs) | |
---|---|---|---|---|---|
Doses received, median (IQR) | 4.0 (1.0) | 5.0 (2.0) | 6.0 (2.0) | 5.0 (0) | 5.0 (1.0) |
Completion of protocol, dogs (%) | 57 (61.3) | 41 (45.1) | 59 (60.8) | 97 (78.2) | 37 (56.9) |
Duration of chemotherapy (days), mean (±SD) | |||||
All dogs | 79 (±29) | 111 (± 39) | 112 (±33) | 73 (±46) | 92 (±32) |
Dog that completed protocol | 92 (±11) | 138 (±17) | 129 (±13) | 75 (±39) | 112 (±18) |
Reasons for early termination (%) | |||||
Metastases | 22 (23.7) | 20 (22.0) | 16 (16.5) | 18 (14.5) | 18 (27.7) |
Owner reasons | 8 (8.6) | 23 (25.3) | 8 (8.3) | 0 (0.0) | 5 (7.7) |
Death attributable to any cause | 1 (1.1) | 0 (0.0) | 1 (1.0) | 5 (4.0) | 1 (1.5) |
Toxicity | 1 (1.1) | 0 (0.0) | 3 (3.3) | 2 (1.6) | 2 (3.1) |
Other | 0 | 1a (1.1) | 2b (2.2) | 1c (1.6) | 2d (3.1) |
Unknown | 3 (3.2) | 1 (1.1) | 4 (4.1) | 0 (0.0) | 1 (1.5) |
Target DI, mg/m2/wk | 100.0 | 100.0 | 60.0 | 15.0 | 10.0 |
Actual DI, mg/m2/wk, mean (±SD) | 85.3 (±14.6) | 84.7 (±11.1) |
C:49.4 (±13.9) D:4.1 (±1.3) |
12.6 (±2.7) | 8.9 (±1.2) |
Target summation DI | 1.0 | 1.0 | 1.2 | 1.0 | 1.0 |
Summation DI, mean (±SD) | 0.9 (±0.1) | 0.8 (±0.1) | 0.9 (±0.1) | 0.8 (±0.2) | 0.9 (±0.1) |
SD, standard deviation; IQR, interquartile range; C, carboplatin; D, doxorubicin.
The dog had a cervical myelopathy of unknown cause.
One dog had hindlimb mobility problems and 1 dog had recurrence at amputation site.
One dog had elbow luxation that had amputation of that limb.
One dog had poor HL mobility and 1 dog had worsening chronic renal disease.